AQP4 and myeloid sarcoma: Patients with NMOSD misclassified as MS were found to have a younger age at onset, more frequent hospitalizations, a longer latency to perform AQP4 autoantibody testing, a longer follow-up period and a higher proportion of patients with frequent and extremely frequent relapses (all P < 0.05).